Cytoprotective effects of octreotide, prostaglandin E1 and diltiazem on experimental hepatic ischemia/reperfusion models [SICANLARDA HEPATIK ISKEMI/REPERFUZYON MODELI UZERINE SOMATOSTATIN ANALOGU OKTREOTID, PROSTAGLANDIN E1 VE DILTIAZEMIN SITOPROTEKTIF ETKISI]
Liver is exposed to ischemic injury during different surgical procedures. During and after hepatic ischemia, various structural and metabolic impairment were previously reported. If has been reported that reperfusion of ischemic tissue could also cause tissue injury. Various agents were tested for prevention of these injuries. The objective of this study was to investigate and compare the usefulness of three different agents on hepatic ischemia/reperfusion injury (I/R). We used a normothermic hepatic I/R model. Albino rats of Wistar strain were divided into five groups as follows: Sham group (SG), control group (CG), octreotide used group (OG), prostaglandin used group (PG) and diltiazem used group (DG). In each group, every rat was exposed to one hour ischemia and 45 minutes reperfusion. Each I/R performed group except control was pretreated with one of the above agents. The biochemical and histological parameters were determined at the end of the experiment. All rats were observed;for postsurgical Seven days and survival time and ratio were determined. We demonstrated that these three agents have beneficial effects, especially on survival ratio. Differentiation on biochemical parameters cannot be overlooked. The best survival ratio was determined for the DG to be (p<0.01), but SGPT, phosphatase, lactic dehydrogenase and levels were significantly lower in OG compared to those of other groups (p<0.01). SGOT value was significantly greater in OG compared to that of PG and DG (p<0.01). Histological alterations were not similar to functional differentiation during early phase. In conclusion, comparison of different agents during hepatic I/R injury showed statistically significant differentiation, but survival ratio for each agent were not similar to biochemical results during early phase. We suggest that there must be new and better studies against postischemic liver injury.